Skip to main content
Premium Trial:

Request an Annual Quote

Where Are They Now?: Mar 1, 2003

Premium

A year ago, GT’s cover story looked at chemical genomics and mentioned several companies in the field, including Ambit, Amphora Discovery, Graffinity Pharmaceuticals, Infinity Pharmaceuticals, Morphochem, and NeoGenesis. Since then, Graffinity hired a new CEO, Klaus Schollmeier; NeoGenesis has announced deals with Mitsubishi and Pharmacia; Eric Eastman headed to Morphochem as the company’s first US division president; and Amphora, after adding a few positions to its management team, signaled possible trouble when it negotiated an agreement for a decreased pay schedule for equipment from partner Caliper Technologies.

The March ’02 issue also featured an article on DoubleTwist, asking, “Is DoubleTwist dead meat?” Turns out, the embattled bioinformatics company died that very month, and all its assets — from computer hardware to a ping-pong table — went to auction in May. Meantime, former CEO John Couch returned to his old digs at Apple, where he’s now vice president of education. And Rob Williamson, who took over as CEO until the company’s demise, wound up at Eos Biotechnology as president and COO.

Our news section last year reported the abrupt departure of Craig Venter from Celera Genomics. After taking some time off to sail in the Caribbean, Venter reinvented himself as head of three nonprofits: the J. Craig Venter Science Foundation, the Institute for Biological Energy Alternatives, and the TIGR Center for the Advancement of Genomics. The centers, which will work together with TIGR, are planning to build and share a new mega-sequencing center (see p. 20), which Venter expects to use for his ambitious plan to sequence 1,000 human genomes. The former Celera president was replaced by Celera Diagnostics president Kathy Ordoñez, who remains head of both companies.

Another news item focused on John Quackenbush, whose work in transcriptomics had finally paid off in a major, annual conference. Quackenbush, well known for his microarray and other research at TIGR, is profiled in this issue of GT (see p. 52).

 

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.